Roche, Trimeris extend research agreement for Fuzeon HIV fusion inhibitor

By Jennifer Chiou

New York, Sept. 7 - Hoffmann-La Roche Inc. and Trimeris, Inc. said they extended their research agreement for the Next Generation Fusion Inhibitor peptides by two years through Dec. 31, 2008.

The agreement was first signed in 2000.

The companies said that the agreement has focused on two peptide classes as candidates: TRI-999 and TRI-1144.

"The collaboration will continue focusing its efforts on conducting further studies with TRI-1144, including the development of extended release formulations for this promising compound in order to meet our desired product profile," Trimeris chief science officer and vice chairman Dani P. Bolognesi said in a news release.

Hoffman-La Roche is part of health care company Roche Holding AG, based in Basel, Switzerland. Trimeris is a biopharmaceutical company located in Morrisville, N.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.